Home > Pulmonology > ERS 2020 > Asthma – What's New > Dupilumab shows long-term efficacy in asthma patients

Dupilumab shows long-term efficacy in asthma patients

Presented By
Dr Michael Wechsler, Prof. Chris Brightling
Conference
ERS 2020
Trial
LIBERTY ASTHMA TRAVERSE, LUSTER
  An open-label extension study found a consistent safety profile and a maintained efficacy of dupilumab over up to 96 weeks. The LIBERTY ASTHMA TRAVERSE trial included asthma patients with uncontrolled moderate-to-severe asthma who had been enrolled in phase 2 and 3 randomised controlled trials for dupilumab treatment [1]. On the other hand, fevipiprant for therapy of severe asthma did not reach significance in the primary objective of the LUSTER-1 and LUSTER-2 trials [2]. The LIBERTY ASTHMA TRAVERSE trial included 2,282 patients from 4 parent studies: QUEST (phase 3), DRI (phase 2b), EXPEDITION (phase 2a), and VENTURE (phase 3) [1]. VENTURE assessed the IL-4 receptor alpha antagonist dupilumab for the treatment of asthma patients taking oral corticosteroids (OCS). In the open-label extension study, all patients were treated with add-on 300 mg ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on